What’s the Dose?
It is doubtful that many in this room would quibble with the statement, in regard to warfarin dosage, that almost every physician appears to behave as if there were no published guidelines for prophylaxis and that he is, so to speak, “therapeutically on his own”. What this means in practical terms to individual patients in each of our own communities is that the therapeutic regimen offered depends on which physician is consulted. Moreover, within each category of practitioner, prophylaxis depends on the hospital entered, the service assigned, the specific attending physician responsible for the patient’s care, and, at some institutions, the house officer on duty at the time of admission. Private office and clinic outpatient management is no more standardized. In recognition of this absence of consensus it is hoped that several of the presentations to follow may provide some common ground concerning therapeutic regimens that will be of intrinsic value for decision making in cardiac and cerebral vascular disease.
KeywordsProthrombin Time Warfarin Dosage Cerebral Vascular Disease Sweet Clover Anti Thrombotic Effect
Unable to display preview. Download preview PDF.
- 1.F.W. Schofield, A brief account of a disease of cattle simulating hemorrhagic septicaemia due to feeding sweet clover, Can Vet Rec 3:74(1922).Google Scholar
- 2.K. P. Link, Anticoagulant from spoiled sweet clover hay, Harvey Lect 39:162(1944).Google Scholar
- 3.A. J. Quick, The prothrombin in hemophilia and in obstructive jaundice, J Biol Chem, 109:lxxiii(1935).Google Scholar
- 5.H. R. Butt, E.V. Allen, and J. L. Bollman, A preChapaution from spoiled sweet clover [3,3′-methylenebis-(4-hydroxycoumarin)] which prolongs coagulation and prothrombin time of the blood: preliminary report of experimental and clinical studies, Proc Staff Meet Mayo Clin, 16:388(1941).Google Scholar
- 6.A. Prandoni, and I. S. Wright, The anticoagulants heparin and the dicumarin -3, 3′-methylenebis-(4-hydroxycoumarin). Bull NY Acad Med, 18:433(1942).Google Scholar
- 7.P. B. Medawar, The Limits of Science, Harper and Row, New York (1984).Google Scholar
- 8.I. S. Wright, C. D. Marple, and D. F. Beck, Myocardial infarction: its clinical manifestations and treatment with anticoagulants. A study of 1031 cases, Grune and Stratton, New York (1954).Google Scholar